HC Wainwright reissued their buy rating on shares of Entera Bio (NASDAQ:ENTX – Free Report) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.
Entera Bio Price Performance
Shares of Entera Bio stock opened at $2.01 on Friday. The business has a 50 day simple moving average of $1.76 and a two-hundred day simple moving average of $1.94. The stock has a market capitalization of $71.93 million, a P/E ratio of -7.18 and a beta of 1.57. Entera Bio has a 12 month low of $0.52 and a 12 month high of $3.35.
Entera Bio (NASDAQ:ENTX – Get Free Report) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of $0.06 million during the quarter. As a group, research analysts anticipate that Entera Bio will post -0.23 EPS for the current fiscal year.
Institutional Inflows and Outflows
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Featured Stories
- Five stocks we like better than Entera Bio
- What Do S&P 500 Stocks Tell Investors About the Market?
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Trading Halts Explained
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- 3 Monster Growth Stocks to Buy Now
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.